Johnson & Johnson Soars Ahead: Strong Q4, Bullish Outlook and Analyst Upgrades

# Johnson & Johnson Stock Soars: Analyzing Q4 Results, 2026 Guidance & Analyst Optimism In this episode, we break down Johnson & Johnson's impressive stock performance as shares surge to $224.50, up 1.4% in mid-day trading. Discover how J&J's solid Q4 results with $24.56B in revenue (up 9.1% YoY) and their bullish 2026 guidance of $99.5-100.5B in sales are driving investor confidence despite challenges like Stelara patent losses. We analyze why top analysts are optimistic, with Guggenheim raising their price target to $240, Morgan Stanley upgrading to "Overweight" with a $262 target, and long-term forecasts predicting prices reaching $259 by April 2026. Learn how J&J's accelerated growth in Innovative Medicine and MedTech segments is positioning this healthcare giant for continued success. Subscribe now for more expert market analysis and stock insights from Quiet Please Productions. #JohnsonAndJohnson #StockAnalysis #InvestmentTips #Healthcare #FinancialForecast #Q4Results #StockMarket For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.